EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lipoprotein(a): A Residual Cardiovascular Risk Factor in Statin-Treated Stroke Survivors

Kévin Chemello, Antonio Gallo, Alexis F Guedon, Romuald Techer, Mikael Croyal, Michael J Swietek, Olivier Meilhac, Pierre Amarenco, Gilles Lambert

JACC: Advances · 2023-09 · 2 (7) · 100557

DOI: 10.1016/j.jacadv.2023.100557 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Advances, 2023-09. Verfasst von Kévin Chemello und 8 weiteren Autor:innen. Beteiligte Einrichtung: Inserm, UMR1188 Diabète athérothrombose Thérapies Réunion Océan Indien (DéTROI), Université de La Réunion, Sainte-Pierre, France. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol levels) trial, atorvastatin (80 mg/d) was compared to placebo in patients with recent stroke or transient ischemic attack (TIA) and no known coronary artery disease.

Objectives

This study aimed to assess the contribution of lipoprotein(a) [Lp(a)] to subsequent cerebrovascular and cardiovascular events in stroke/TIA survivors.

Methods

Lp(a) levels and apolipoprotein(a) [apo(a)] isoform size were determined by liquid-chromatography mass spectrometry in samples collected at baseline from 2,814 SPARCL participants (1,418 randomized to atorvastatin and 1,396 to placebo). Within each treatment arm, patients in the highest quartile (≥84.0 nmol/L) were compared with those in the lowest quartiles of Lp(a) concentrations. Patients in the lowest quartile (≤25.9 Kringle IV domains) of apo(a) isoform sizes were compared with those in the highest quartiles. Multivariable-adjusted HRs were calculated using Cox proportional regression models.

Results

There was no significant association between Lp(a) concentrations or apo(a) isoform sizes and the risk of recurrent stroke, the primary outcome of SPARCL, or cerebrovascular events in patients randomized to atorvastatin or placebo. In contrast, in patients randomized to atorvastatin, elevated Lp(a) concentrations and short apo(a) isoforms were positively and independently associated with an increased risk of coronary events (HR: 1.607 [95% CI: 1.007-2.563] and HR: 2.052 [95% CI: 1.303-3.232]). No such association was found in patients randomized to placebo (HR: 1.025 [95% CI: 0.675-1.555] and HR: 1.097 [95% CI: 0.735-1.637]).

Conclusions

Lp(a) contributes to the residual coronary artery disease risk of statin-treated stroke/TIA survivors, paving the way for use of therapies targeting Lp(a) in this population with stroke. (Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke [SPARCL]; NCT00147602).

Schlagwörter

Stichwörter der Autor:innen

CADatorvastatinlipoprotein(a)residual riskstroke

Autor:innen und Institutionen

  • Inserm, UMR1188 Diabète athérothrombose Thérapies Réunion Océan Indien (DéTROI), Université de La Réunion, Sainte-Pierre, France.
  • Department of Endocrinology and Prevention of Cardiovascular Disease, Institute of Cardio Metabolism and Nutrition (ICAN), Sorbonne Université Pitié-Salpêtrière Hospital, SU-APHP, Paris, France.
  • APHP, Service de Médecine Interne, Département Hospitalo-Universitaire Inflammation Immunopathologie Biothérapie (DMUi3), Sorbonne Université, Paris, France.
  • CHU Nantes, CNRS, Inserm, BioCore, US16, SFR Bonamy, Nantes Université, Nantes, France.
  • CHU Nantes, CNRS, Inserm, Institut du Thorax, Nantes Université, Nantes, France.
  • CRNH-Ouest Mass Spectrometry Core Facility, Nantes, France.

Zitieren

APA

Chemello, K., Gallo, A., Guedon, A. F., Techer, R., Croyal, M., Swietek, M. J., Meilhac, O., Amarenco, P., & Lambert, G. (2023). Lipoprotein(a): A Residual Cardiovascular Risk Factor in Statin-Treated Stroke Survivors. JACC: Advances, 2(7), 100557. https://doi.org/10.1016/j.jacadv.2023.100557

Vancouver

Chemello K, Gallo A, Guedon AF, Techer R, Croyal M, Swietek MJ, et al. Lipoprotein(a): A Residual Cardiovascular Risk Factor in Statin-Treated Stroke Survivors. JACC: Advances. 2023;2(7):100557. doi:10.1016/j.jacadv.2023.100557

BibTeX
@article{Chemello2023,
  author = {Chemello, Kévin and Gallo, Antonio and Guedon, Alexis F and Techer, Romuald and Croyal, Mikael and Swietek, Michael J and Meilhac, Olivier and Amarenco, Pierre and Lambert, Gilles},
  title = {Lipoprotein(a): A Residual Cardiovascular Risk Factor in Statin-Treated Stroke Survivors},
  journal = {JACC: Advances},
  year = {2023},
  volume = {2},
  number = {7},
  pages = {100557},
  doi = {10.1016/j.jacadv.2023.100557}
}
Kostenlos starten →